Akebia Therapeutics Inc logo

Akebia Therapeutics Inc

FRA:AX9 (USA)  
€ 1.66 (-8.79%) Mar 28
At Loss
Market Cap:
€ 353.85M ($ 381.73M)
Enterprise V:
€ 358.66M ($ 386.91M)
Volume:
11.84K
Avg Vol (2M):
1.59K
Also Trade In:
Volume:
11.84K
At Loss

Business Description

Akebia Therapeutics Inc logo
Akebia Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US00972D1054
Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Name Current Vs Industry Vs History
Cash-To-Debt 0.89
Equity-to-Asset -0.13
Debt-to-Equity -1.57
Debt-to-EBITDA -14.21
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -8.01
Distress
Grey
Safe
Beneish M-Score -2.79
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 42.56
9-Day RSI 50.54
14-Day RSI 52.99
6-1 Month Momentum % 38.22
12-1 Month Momentum % 149.21

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.18
Quick Ratio 1.03
Cash Ratio 0.43
Days Inventory 96.62
Days Sales Outstanding 52.3
Days Payable 65.65

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.5
Shareholder Yield % 11.9

Financials (Next Earnings Date:2024-05-08 Est.)

FRA:AX9's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Akebia Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 180.443
EPS (TTM) (€) -0.261
Beta 1.48
Volatility % 112.51
14-Day RSI 52.99
14-Day ATR (€) 0.176222
20-Day SMA (€) 1.5787
12-1 Month Momentum % 149.21
52-Week Range (€) 0.4475 - 2.85
Shares Outstanding (Mil) 209.37

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Akebia Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Akebia Therapeutics Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Akebia Therapeutics Inc Frequently Asked Questions

What is Akebia Therapeutics Inc(FRA:AX9)'s stock price today?
The current price of FRA:AX9 is €1.66. The 52 week high of FRA:AX9 is €2.85 and 52 week low is €0.45.
When is next earnings date of Akebia Therapeutics Inc(FRA:AX9)?
The next earnings date of Akebia Therapeutics Inc(FRA:AX9) is 2024-05-08 Est..
Does Akebia Therapeutics Inc(FRA:AX9) pay dividends? If so, how much?
Akebia Therapeutics Inc(FRA:AX9) does not pay dividend.

Press Release

Subject Date
No Press Release